Therapeutic Targeting of the IGF Axis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and development, and when deregulated makes an important contribution to disease. Here, we review the functions mediated by ligand-induced IGF axis activation, and discuss the evidence for the involvement of IGF signaling in the pathogenesis of cancer, endocrine disorders including acromegaly, diabetes and thyroid eye disease, skin diseases such as acne and psoriasis, and the frailty that accompanies aging. We discuss the use of IGF axis inhibitors, focusing on the different approaches that have been taken to develop effective and tolerable ways to block this important signaling pathway. We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Role of insulin-like growth factors in embryonic and postnatal growth
Baker, J., Liu, J.-P., Robertson, E. J., & Efstratiadis, A. (1993) · Cell · doi:10.1016/s0092-8674(05)80085-6 · Cited by 2,463
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice
Holzenberger, M., Dupont, J., Ducos, B., Leneuve, P., Géloën, A., Even, P. C., Cervera, P., & Le Bouc, Y. (2003) · Nature · doi:10.1038/nature01298 · Cited by 2,109 · cited 1×
“Paradoxically, the IGF axis is the target of inactivating mutations in long-lived model organisms including Caenorhabditis elegans, Drosophila melanogaster and mice [107,108].”
BackgroundRenehan, A. G., Zwahlen, M., Minder, C., O'Dwyer, S. T., Shalet, S. M., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16044-3 · Cited by 1,697
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
The insulin and insulin-like growth factor receptor family in neoplasia: an update
Pollak, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3215 · Cited by 1,116
Levine, M. E., Suarez, J. A., Brandhorst, S., Balasubramanian, P., Cheng, C.-W., Madia, F., Fontana, L., Mirisola, M. G., Guevara-Aguirre, J., Wan, J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.02.006 · Cited by 910
Interventions to slow aging in humans: are we ready?
Longo, V. D., Antebi, A., Bartke, A., Barzilai, N., Brown‐Borg, H. M., Caruso, C., Curiel, T. J., Cabo, R., Franceschi, C., Gems, D., et al. (2015) · Aging Cell · doi:10.1111/acel.12338 · Cited by 592
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
Moses, A. C., Young, S. C., Morrow, L. A., O'Brien, M., & Clemmons, D. R. (1996) · Diabetes · doi:10.2337/diab.45.1.91 · Cited by 291 · cited 1×
“Recombinant human IGF-1 (rhIGF-1) has been evaluated as treatment for diabetes, with evidence of improved glycemic control but significant adverse effects including worsening diabetic retinopathy [83,84].”
BackgroundBehjati, S., Tarpey, P. S., Haase, K., Ye, H., Young, M. D., Alexandrov, L. B., Farndon, S. J., Collord, G., Wedge, D. C., Martincorena, I., et al. (2017) · Nature Communications · doi:10.1038/ncomms15936 · Cited by 261
Insulin-Like Growth Factor 2 in Development and Disease: A Mini-Review
Bergman, D., Halje, M., Nordin, M., & Engström, W. (2013) · Gerontology · doi:10.1159/000343995 · Cited by 260 · cited 1×
“Secondly, the expression of IGF-2 is regulated by genomic imprinting, being expressed in normal tissues only from the paternal allele [27].”
Backgroundc-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer
Vleugel, M. M., Greijer, A. E., Bos, R., van der Wall, E., & van Diest, P. J. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.01.022 · Cited by 250
Ulanet, D. B., Ludwig, D. L., Kahn, C. R., & Hanahan, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914076107 · Cited by 235
Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice
Mao, K., Quipildor, G. F., Tabrizian, T., Novaj, A., Guan, F., Walters, R. O., Delahaye, F., Hubbard, G. B., Ikeno, Y., Ejima, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04805-5 · Cited by 167
Sclafani, F., Kim, T. Y., Cunningham, D., Kim, T. W., Tabernero, J., Schmoll, H. J., Roh, J. K., Kim, S. Y., Park, Y. S., Guren, T. K., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv258 · Cited by 92
Effect of insulin-like growth factor-1 deficiency or administration on the occurrence of acne
Ben‐Amitai, D., & Laron, Z. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03896.x · Cited by 88
Cited by
Insulin-like growth factors: Ligands, binding proteins, and receptors
LeRoith, D., Holly, J. M. P., & Forbes, B. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101245 · Cited by 303
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32
Revealing the Potency of Growth Factors in Bovine Colostrum
Yalçıntaş, Y. M., Duman, H., López, J. M. M., Portocarrero, A. C. M., Lombardo, M., Khallouki, F., Koch, W., Bordiga, M., El-Seedi, H., Raposo, A., et al. (2024) · Nutrients · doi:10.3390/nu16142359 · Cited by 31
“Thus, targeting the IGF-2 signaling pathway is being investigated as a possible therapeutic approach for the treatment of cancer [56,57].”
Background
Metadata
- Authors
- Osher, E., & Macaulay, V. M.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-08-14
- Volume
- 8
- Issue
- 8
- Pages
- 895
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2968300883
- Cited by
- 153
- References
- 18
- FWCI
- 14.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.